NCT07107126View on ClinicalTrials.gov

Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

18

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

December 1, 2028

Study Completion Date

December 1, 2028

Conditions

Acute Myeloid LeukemiaMyelodysplastic Syndrome

Interventions

DRUG

RPT1G

RPT1G is a selective hyperbolic NAMPT inhibitor. RPT1G is administered orally.

All Listed Sponsors

lead

Remedy Plan, Inc.

INDUSTRY